A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis
Phase of Trial: Phase 0
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Saracatinib (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms SCRIPT
- 12 Aug 2019 Status changed from not yet recruiting to recruiting.
- 25 Feb 2019 Planned initiation date changed from 1 Dec 2018 to 11 Apr 2019.
- 24 Sep 2018 Planned initiation date changed from 1 Sep 2018 to 1 Dec 2018.